Maria Sjostrand

Sanavia Oncology Inc.

We are a New York-based biotech company with a team of drug developers from Memorial Sloan-Kettering Cancer Center, Rockefeller University, Weill Cornell Medicine and Columbia University. Majority of cancer patients do not benefit from currently available therapies due to drug resistance. We are developing novel immunotherapies that can safely and effectively overcome that drug resistance and improve patients' lives. We use our proprietary platform to discover clinically relevant, cancer-specific epitopes in different types of drug resistant tumors and to generate antibodies with atomic-level specificity to these epitopes. We combine high throughput sequencing, single-molecule super-resolution microscopy, 3D protein modeling and artificial intelligence with novel in vivo models for validating our targets and developing next generation immunotherapies that can safely and effectively eliminate drug-resistant tumors.